Join the club for FREE to access the whole archive and other member benefits.

Wolf Reik

Principal Investigator at Babraham Institute Cambridge, future member of Altos Labs

Wolf Reik obtained his MD from the University of Hamburg. He did his thesis work with Rudolf Jaenisch, and postdoctoral work with Azim Surani in Cambridge. He was a Fellow of the Lister Institute of Preventive Medicine at Cambridge and the Institute’s Associate Director (2004-2020) and Head of the Epigenetics Programme (2008-2020). From May 2020 – July 2021 he held the position of Acting Director and then permanent Director for the Institute. He is honorary Professor of Epigenetics at the University of Cambridge, Associate Faculty at the Wellcome Sanger Institute, Affiliate Faculty at the Stem Cell Institute and a member of the Centre for Trophoblast Research.

His research interests are in mammalian epigenetics, particularly in epigenetic reprogramming during mammalian development and its role in stem cell biology, inheritance and ageing. He has published more than 250 research articles with an h-index of 122. He won the Wellcome Prize in Physiology and is a member of EMBO and the Academia Europaea, and a Fellow of the Academy of Medical Sciences and the Royal Society.

Visit website: https://www.babraham.ac.uk/people/member/272

 wolf-reik-907aa9130

 ReikLab

See also: Institute Babraham Institute - Life sciences research institution and a partner organisation of the University of Cambridge.

Details last updated 21-Jan-2022

Wolf Reik is also referenced in the following:

Altos Labs

Biotechnology company focused on cellular rejuvenation programming

Wolf Reik News

Biological age of human skin cells reduced by 30 years (transcriptome and methylation clocks)

Biological age of human skin cells reduced by 30 years (transcriptome and methylation clocks)

BBC - 08-Apr-2022

Transient reprogramming is progressing fast - how long before the first skincare product is launched?

Altos Labs comes out of stealth with $3 billion of capital

Altos Labs comes out of stealth with $3 billion of capital

Genetic Engineering & Biotechnology News (GEN) - 19-Jan-2022

Huge backing that cellular reprogramming can have a significant impact on health and ageing